Literature DB >> 15177931

Prosomatostatin is proteolytically processed at the amino terminal segment by subtilase SKI-1.

R Mouchantaf1, H L Watt, T Sulea, N G Seidah, H Alturaihi, Y C Patel, U Kumar.   

Abstract

Processing of prohormones to generate active products typically occurs at basic residues via cleavage by proprotein convertases. A less common type of cleavage is mediated at hydrophobic (L, V, F, N) or small amino acid (A, T, S) residues. Efforts to identify the proteinases responsible for processing precursors at their hydrophobic amino acids has led to the recent cloning of a new type-1 membrane-bound subtilase called SKI-1. The NH2-terminal region of prosomatostatin, previously shown to contain a sorting signal for the regulated secretory pathways, is processed to generate PSST[1-10]. The exact cleavage mechanism is unknown, but has been assumed to involve monobasic processing at Lys13 followed by carboxypeptidase trimming. We found that K13A mutation did not block PSST[1-10] production. Since the prosomatostatin sequence R8-Q9-F10-L11 \ qualifies as a potential SKI-1 substrate, using a vaccinia virus expression system along with HPLC and radioimmunoassays, we observed that overexpression of recombinant SKI-1 in COS-1 and HEK-293 cells significantly increased the production of PSST[1-10]. Additionally, in CHO cells lacking SKI-1, there was a significant reduction in PSST[1-10] production which could be increased upon SKI-1 stimulation. Mutagenesis studies showed that efficient processing of PSST to PSST[1-10] required the RXRXXL motif. However, this NH2-terminal cleavage was not a prerequisite for the formation of SST-14 and SST-28.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15177931     DOI: 10.1016/j.regpep.2004.02.022

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  4 in total

Review 1.  Processing of peptide and hormone precursors at the dibasic cleavage sites.

Authors:  Mohamed Rholam; Christine Fahy
Journal:  Cell Mol Life Sci       Date:  2009-03-20       Impact factor: 9.261

Review 2.  The proprotein convertases are potential targets in the treatment of dyslipidemia.

Authors:  Nabil G Seidah; Annik Prat
Journal:  J Mol Med (Berl)       Date:  2007-03-10       Impact factor: 4.599

Review 3.  Pro-protein convertases in intermediary metabolism: islet hormones, brain/gut hormones and integrated physiology.

Authors:  Dominique Bataille
Journal:  J Mol Med (Berl)       Date:  2007-03-14       Impact factor: 4.599

4.  The relationship between N-terminal prosomatostatin, all-cause and cardiovascular mortality in patients with type 2 diabetes mellitus (ZODIAC-35).

Authors:  Peter R van Dijk; Gijs W D Landman; Larissa van Essen; Joachim Struck; Klaas H Groenier; Henk J G Bilo; Stephan J L Bakker; Nanne Kleefstra
Journal:  BMC Endocr Disord       Date:  2015-04-14       Impact factor: 2.763

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.